Valvular & structural heart diseaseCohort study

Ascending aorta and pure aortic regurgitation transcatheter aortic valve replacement: insights from the National Transcatheter Valve Therapeutics Registry

HeartPublished

  • national registry-based, multicentre, retrospective cohort study

Authors' conclusion

In this large national registry-based observational and exploratory study, we identified the ascending aorta as the key predictor for PNAR patients who underwent self-expandable TF-TAVR. Patients with ascending aortic diameters greater than 41.6 mm may have a significantly higher 30-day all-cause mortality rate.

Study context

Population
Patients with pure native aortic regurgitation (PNAR) undergoing self-expandable transfemoral transcatheter aortic valve replacement (TF-TAVR), enrolled from the NTCVR in China between January 2017 and December 2023patients with PNAR from 72 centres in China
Participants
890 patients
Outcome
all-cause mortality
Follow-up
30 days

Main finding

As reported in the abstract

30-day all-cause mortality

2.7%

Observational data: associations, not effects.

Further findings

Risk factors for 30-day all-cause mortality (multivariate logistic regression)

ComparisonOR (95% CI)P value
diameter of the ascending aorta1.103 (1.005–1.212)P = 0.039
renal insufficiency4.602 (1.455–14.553)P = 0.009

30-day all-cause mortality by ascending aorta diameter (XGBoost, Shapley Additive explanations)

ComparisonOR (95% CI)P value
ascending aorta greater than 41.6 mm · significantly higher 30-day all-cause mortality rate5.027 (2.042–12.696)P = 0.0004

In-hospital all-cause mortality

in-hospital all-cause mortality
2.0%

30-day all-cause mortality by ascending aorta diameter (XGBoost, Shapley Additive explanations)

diameter of the ascending aorta as the key predictor

Predictors of technical success

NYHA class III/IV and annulus long diameter were predictors of technical success in multivariate analysis

Original publication

Ascending aorta and pure aortic regurgitation transcatheter aortic valve replacement: insights from the National Transcatheter Valve Therapeutics Registry. Heart. Published 7 August 2026. doi:10.1136/heartjnl-2025-327742

Summarised from the published abstract; every number is checked against it